A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

60

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Related Post

A/Prof Hien Le addresses the 2025 TROG Concept Development Workshop
4 December, 2025

TROG Concept Development Workshop sows seeds for innovative new research

LATEST NEWS: 4 December 2025 TROG provided a kick-start

26 November, 2025

TROG Member Prof Paul Keall’s innovative research recognised in two Premier’s Awards

LATEST NEWS; 26 November 2025 Medical physics researcher and